IN2014MN00987A - - Google Patents
Info
- Publication number
- IN2014MN00987A IN2014MN00987A IN987MUN2014A IN2014MN00987A IN 2014MN00987 A IN2014MN00987 A IN 2014MN00987A IN 987MUN2014 A IN987MUN2014 A IN 987MUN2014A IN 2014MN00987 A IN2014MN00987 A IN 2014MN00987A
- Authority
- IN
- India
- Prior art keywords
- compounds
- cancer
- diseases
- processes
- preparation
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- -1 naphthyridine derivative compounds Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161552883P | 2011-10-28 | 2011-10-28 | |
| GBGB1118675.6A GB201118675D0 (en) | 2011-10-28 | 2011-10-28 | New compounds |
| PCT/GB2012/052669 WO2013061077A1 (en) | 2011-10-28 | 2012-10-26 | New compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN00987A true IN2014MN00987A (OSRAM) | 2015-04-24 |
Family
ID=45375501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN987MUN2014 IN2014MN00987A (OSRAM) | 2011-10-28 | 2012-10-26 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US9309241B2 (OSRAM) |
| EP (1) | EP2776436B1 (OSRAM) |
| JP (1) | JP6022588B2 (OSRAM) |
| KR (1) | KR102027602B1 (OSRAM) |
| CN (1) | CN104011052B (OSRAM) |
| AU (1) | AU2012328167B9 (OSRAM) |
| BR (1) | BR112014010179B1 (OSRAM) |
| CA (1) | CA2853367C (OSRAM) |
| DK (1) | DK2776436T3 (OSRAM) |
| ES (1) | ES2731216T3 (OSRAM) |
| GB (1) | GB201118675D0 (OSRAM) |
| HR (1) | HRP20190994T1 (OSRAM) |
| HU (1) | HUE044576T2 (OSRAM) |
| IN (1) | IN2014MN00987A (OSRAM) |
| LT (1) | LT2776436T (OSRAM) |
| MX (1) | MX349004B (OSRAM) |
| RU (1) | RU2629194C2 (OSRAM) |
| SI (1) | SI2776436T1 (OSRAM) |
| WO (1) | WO2013061077A1 (OSRAM) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
| GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| AR090844A1 (es) * | 2012-04-27 | 2014-12-10 | Actelion Pharmaceuticals Ltd | Proceso para elaborar derivados de naftiridina |
| GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| AR094812A1 (es) | 2013-02-20 | 2015-08-26 | Eisai R&D Man Co Ltd | Derivado de piridina monocíclico como inhibidor del fgfr |
| GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
| JP6112724B2 (ja) * | 2013-10-31 | 2017-04-12 | 日本化薬株式会社 | １，５−ナフチリジン誘導体およびそれを有効成分として含んでなる殺虫剤 |
| JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
| WO2015144808A1 (en) | 2014-03-26 | 2015-10-01 | Astex Therapeutics Ltd | Combinations of an fgfr inhibitor and an igf1r inhibitor |
| AU2015238301B2 (en) | 2014-03-26 | 2020-06-25 | Astex Therapeutics Ltd | Combinations |
| JP6783224B2 (ja) | 2014-04-04 | 2020-11-11 | デル マー ファーマシューティカルズ | 肺の非小細胞癌腫及び卵巣癌を処置するためのジアンヒドロガラクチトール及びその類縁体又は誘導体の使用 |
| SG11201700703XA (en) | 2014-08-18 | 2017-03-30 | Eisai R&D Man Co Ltd | Salt of monocyclic pyridine derivative and crystal thereof |
| JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
| KR102537152B1 (ko) | 2015-03-25 | 2023-05-26 | 국립연구개발법인 고쿠리츠간켄큐센터 | 담관암에 대한 치료제 |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| DK3353177T3 (da) | 2015-09-23 | 2020-08-24 | Janssen Pharmaceutica Nv | Tricykliske heterocykler til behandling af cancer |
| AU2016328693B2 (en) * | 2015-09-23 | 2021-03-11 | Janssen Pharmaceutica Nv | Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer |
| US9855255B1 (en) | 2017-05-26 | 2018-01-02 | King Saud University | Substituted naphthyridinyl hydrazines as anti-liver cancer agents |
| CN111712245A (zh) | 2018-03-28 | 2020-09-25 | 卫材R&D管理有限公司 | 用于肝细胞癌的治疗剂 |
| CN110128505A (zh) * | 2019-05-21 | 2019-08-16 | 梯尔希（南京）药物研发有限公司 | 一种戈舍瑞林杂质的合成方法 |
| WO2021146163A1 (en) * | 2020-01-17 | 2021-07-22 | Beta Pharma, Inc. | Pyridazine and 1,2,4-triazine derivatives as fgfr kinase inhibitors |
Family Cites Families (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2940972A (en) | 1957-06-27 | 1960-06-14 | Thomae Gmbh Dr K | Tri-and tetra-substituted pteridine derivatives |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| GB9125001D0 (en) | 1991-11-25 | 1992-01-22 | Ici Plc | Heterocyclic compounds |
| US5700823A (en) | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
| US6331555B1 (en) | 1995-06-01 | 2001-12-18 | University Of California | Treatment of platelet derived growth factor related disorders such as cancers |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| US5882864A (en) | 1995-07-31 | 1999-03-16 | Urocor Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| TW472045B (en) | 1996-09-25 | 2002-01-11 | Astra Ab | Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation |
| IL133009A0 (en) | 1997-05-28 | 2001-03-19 | Aventis Pharm Prod Inc | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
| UA71555C2 (en) | 1997-10-06 | 2004-12-15 | Zentaris Gmbh | Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives |
| AU3033500A (en) | 1999-01-15 | 2000-08-01 | Agouron Pharmaceuticals, Inc. | Non-peptide glp-1 agonists |
| YU18502A (sh) | 1999-09-15 | 2004-12-31 | Warner-Lambert Company | Pteridinoni kao inhibitori kinaza |
| DE10013318A1 (de) | 2000-03-17 | 2001-09-20 | Merck Patent Gmbh | Formulierung enthaltend Chinoxalinderivate |
| WO2002076985A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| JP4286146B2 (ja) | 2001-12-18 | 2009-06-24 | メルク エンド カムパニー インコーポレーテッド | メタボトロピックグルタミン酸受容体−５のヘテロアリール置換ピラゾール系調節剤 |
| PT1463506E (pt) | 2001-12-24 | 2009-12-10 | Astrazeneca Ab | Derivados de quinazolina substituídos como inibidores de aurora cinases |
| JP2003213463A (ja) | 2002-01-17 | 2003-07-30 | Sumitomo Chem Co Ltd | 金属腐食防止剤および洗浄液 |
| US7265378B2 (en) | 2002-07-10 | 2007-09-04 | E. I. Du Pont De Nemours And Company | Electronic devices made with electron transport and/or anti-quenching layers |
| US7825132B2 (en) | 2002-08-23 | 2010-11-02 | Novartis Vaccines And Diagnostics, Inc. | Inhibition of FGFR3 and treatment of multiple myeloma |
| MXPA05003477A (es) | 2002-10-03 | 2005-07-22 | Targegen Inc | Agentes vasculo-estaticos y metodos de uso de los mismos. |
| AR043059A1 (es) | 2002-11-12 | 2005-07-13 | Bayer Pharmaceuticals Corp | Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiper-proliferativos |
| US7098332B2 (en) | 2002-12-20 | 2006-08-29 | Hoffmann-La Roche Inc. | 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones |
| DE602004021558D1 (de) * | 2003-01-17 | 2009-07-30 | Warner Lambert Co | 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation |
| WO2004098494A2 (en) | 2003-04-30 | 2004-11-18 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| US7244739B2 (en) | 2003-05-14 | 2007-07-17 | Torreypines Therapeutics, Inc. | Compounds and uses thereof in modulating amyloid beta |
| DE10323345A1 (de) | 2003-05-23 | 2004-12-16 | Zentaris Gmbh | Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren |
| ME00541B (me) | 2003-05-23 | 2011-10-10 | Zentaris Gmbh | NOVI PIRIDOPIRAZINI I NJlUHOVA UPOTREBA KAO MODULATORA KlNAZA |
| WO2005007099A2 (en) | 2003-07-10 | 2005-01-27 | Imclone Systems Incorporated | Pkb inhibitors as anti-tumor agents |
| EP1646383A4 (en) | 2003-07-21 | 2009-03-25 | Bethesda Pharmaceuticals Inc | DESIGN AND SYNTHESIS OF OPTIMIZED LIGANDS FOR PPAR |
| PL1673092T3 (pl) | 2003-10-17 | 2008-01-31 | 4 Aza Ip Nv | Pochodne pterydyny podstawione heterocyklem i ich zastosowanie w leczeniu |
| EP1682529A4 (en) | 2003-11-07 | 2010-06-30 | Novartis Vaccines & Diagnostic | PROCESS FOR SYNTHESIS OF CHINOLINONE COMPOUNDS |
| SG150533A1 (en) | 2003-11-20 | 2009-03-30 | Janssen Pharmaceutica Nv | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2- quinoxalinones as poly(adp-ribose) polymerase inhibitors |
| KR100861515B1 (ko) | 2003-11-24 | 2008-10-02 | 에프. 호프만-라 로슈 아게 | 피라졸릴 및 이미다졸릴 피리미딘 |
| AU2004303602C1 (en) | 2003-12-23 | 2009-05-28 | Astex Therapeutics Limited | Pyrazole derivatives as protein kinase modulators |
| US7205316B2 (en) | 2004-05-12 | 2007-04-17 | Abbott Laboratories | Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands |
| US7098222B2 (en) | 2004-05-12 | 2006-08-29 | Abbott Laboratories | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
| AU2005278959A1 (en) | 2004-08-31 | 2006-03-09 | Astrazeneca Ab | Quinazolinone derivatives and their use as B-Raf inhibitors |
| CA2583192A1 (en) | 2004-10-14 | 2006-04-20 | F. Hoffmann-La Roche Ag | 1,5-naphthyridine azolidinones having cdk1 antiproliferative activity |
| CN102049048B (zh) | 2004-12-24 | 2013-12-25 | 西芬克斯医药有限公司 | 治疗或预防的方法 |
| WO2006084338A1 (en) | 2005-02-14 | 2006-08-17 | Bionomics Limited | Novel tubulin polymerisation inhibitors |
| EP1853261B1 (de) | 2005-03-03 | 2017-01-11 | Universität des Saarlandes | Selektive hemmstoffe humaner corticoidsynthasen |
| JP2008540535A (ja) | 2005-05-12 | 2008-11-20 | メルク エンド カムパニー インコーポレーテッド | チロシンキナーゼ阻害剤 |
| CN101223170A (zh) * | 2005-05-18 | 2008-07-16 | 惠氏公司 | Tpl2激酶的4,6-二氨基-[1,7]萘啶-3-甲腈抑制剂以及其制备和使用方法 |
| GB0513692D0 (en) | 2005-07-04 | 2005-08-10 | Karobio Ab | Novel pharmaceutical compositions |
| US8217042B2 (en) | 2005-11-11 | 2012-07-10 | Zentaris Gmbh | Pyridopyrazines and their use as modulators of kinases |
| JP5527972B2 (ja) | 2005-11-11 | 2014-06-25 | エテルナ ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規のピリドピラジン及び前記ピリドピラジンをキナーゼのモジュレーターとして用いる使用 |
| EP1790342A1 (de) | 2005-11-11 | 2007-05-30 | Zentaris GmbH | Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege |
| AP3433A (en) | 2005-12-21 | 2015-10-31 | Janssen Pharmaceutica Nv | Triazolopyridazines as tyrosine kinase modultors |
| US7998978B2 (en) | 2006-05-01 | 2011-08-16 | Pfizer Inc. | Substituted 2-amino-fused heterocyclic compounds |
| GB0609621D0 (en) | 2006-05-16 | 2006-06-21 | Astrazeneca Ab | Novel co-crystal |
| WO2007135027A1 (de) | 2006-05-24 | 2007-11-29 | Boehringer Ingelheim International Gmbh | Substituierte pteridine, die mit einem viergliedrigen heterocyclus substituiert sind |
| US20100016293A1 (en) | 2006-07-03 | 2010-01-21 | Rogier Adriaan Smits | Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use |
| JP2008127446A (ja) | 2006-11-20 | 2008-06-05 | Canon Inc | １，５−ナフチリジン化合物及び有機発光素子 |
| EP2104501B1 (en) | 2006-12-13 | 2014-03-12 | Merck Sharp & Dohme Corp. | Methods of cancer treatment with igf1r inhibitors |
| MX2009006688A (es) | 2006-12-21 | 2009-06-30 | Plexxikon Inc | Compuestos y metodos para modulacion de cinasas, e indicaciones para ello. |
| AU2007337886C1 (en) | 2006-12-22 | 2014-10-16 | Astex Therapeutics Limited | Bicyclic heterocyclic compounds as FGFR inhibitors |
| AU2007336893A1 (en) | 2006-12-22 | 2008-07-03 | Novartis Ag | Quinazolines for PDK1 inhibition |
| KR20080062876A (ko) | 2006-12-29 | 2008-07-03 | 주식회사 대웅제약 | 신규한 항진균성 트리아졸 유도체 |
| EP1990342A1 (en) | 2007-05-10 | 2008-11-12 | AEterna Zentaris GmbH | Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof |
| US20100234386A1 (en) | 2007-05-10 | 2010-09-16 | Chaudhari Amita | Quinoxaline derivatives as pi3 kinase inhibitors |
| JP2010529031A (ja) | 2007-05-29 | 2010-08-26 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Ｐｉ３キナーゼ阻害剤としてのナフチリジン誘導体 |
| AR066879A1 (es) | 2007-06-08 | 2009-09-16 | Novartis Ag | Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus |
| JP5548123B2 (ja) | 2007-06-21 | 2014-07-16 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ６−｛ジフルオロ［６−（１−メチル−１Ｈ−ピラゾル−４−イル）［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン−３−イル］メチル｝キノリンの多形および水和物の形態、塩、ならびに製造方法 |
| WO2009021083A1 (en) | 2007-08-09 | 2009-02-12 | Smithkline Beecham Corporation | Quinoxaline derivatives as pi3 kinase inhibitors |
| WO2009019518A1 (en) | 2007-08-09 | 2009-02-12 | Astrazeneca Ab | Pyrimidine compounds having a fgfr inhibitory effect |
| US20090054304A1 (en) | 2007-08-23 | 2009-02-26 | Kalypsys, Inc. | Heterocyclic modulators of tgr5 for treatment of disease |
| US8309718B2 (en) | 2007-11-16 | 2012-11-13 | Incyte Corporation | 4-pyrazolyl-N-arylpyrimidin-2-amines and 4-pyrazolyl-N-heteroarylpyrimidin-2-amines as janus kinase inhibitors |
| MX2010012064A (es) | 2008-05-05 | 2010-12-06 | Schering Corp | Uso secuencial de agentes quimioterapeuticos citotoxicos para el tratamiento de cancer. |
| ES2554513T3 (es) | 2008-05-23 | 2015-12-21 | Novartis Ag | Derivados de quinolinas y quinoxalinas como inhibidores de la proteína tirosina quinasa |
| EP2356116A1 (en) | 2008-11-20 | 2011-08-17 | OSI Pharmaceuticals, Inc. | Substituted pyrroloý2,3-b¨-pyridines and-pyrazines |
| AU2010206161B2 (en) | 2009-01-21 | 2014-08-07 | Basilea Pharmaceutica Ag | Novel bicyclic antibiotics |
| WO2010088177A1 (en) * | 2009-02-02 | 2010-08-05 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| TW201041888A (en) | 2009-05-06 | 2010-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| EP2440547B1 (en) | 2009-06-12 | 2022-11-30 | Abivax | New chemical molecules that inhibit the splicing mechanism for the treatment of diseases resulting from splicing defects |
| JP5696856B2 (ja) | 2009-09-03 | 2015-04-08 | バイオエナジェニックス | Ｐａｓｋの阻害用複素環式化合物 |
| WO2011026579A1 (en) | 2009-09-04 | 2011-03-10 | Bayer Schering Pharma Aktiengesellschaft | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors |
| EP2332939A1 (en) * | 2009-11-26 | 2011-06-15 | Æterna Zentaris GmbH | Novel Naphthyridine derivatives and the use thereof as kinase inhibitors |
| WO2011126903A2 (en) | 2010-03-30 | 2011-10-13 | Verseon, Inc. | Multisubstituted aromatic compounds as inhibitors of thrombin |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| US8513421B2 (en) | 2010-05-19 | 2013-08-20 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| EP2575462B1 (en) | 2010-05-24 | 2016-06-22 | Intellikine, LLC | Heterocyclic compounds and uses thereof |
| GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| CN102532141A (zh) | 2010-12-08 | 2012-07-04 | 中国科学院上海药物研究所 | [1，2，4]三唑并[4，3-b][1，2，4]三嗪类化合物、其制备方法和用途 |
| PE20140293A1 (es) | 2011-01-31 | 2014-03-19 | Novartis Ag | Novedosos derivados heterociclicos |
| WO2012148540A1 (en) | 2011-02-23 | 2012-11-01 | Intellikine, Llc | Combination of kanase inhibitors and uses threof |
| WO2012118492A1 (en) | 2011-03-01 | 2012-09-07 | Array Biopharma Inc. | Heterocyclic sulfonamides as raf inhibitors |
| CN107245056A (zh) | 2011-08-26 | 2017-10-13 | 润新生物公司 | 化学实体、组合物及方法 |
| WO2013040515A1 (en) | 2011-09-14 | 2013-03-21 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| US9249110B2 (en) | 2011-09-21 | 2016-02-02 | Neupharma, Inc. | Substituted quinoxalines as B-raf kinase inhibitors |
| EP2763994A4 (en) | 2011-10-04 | 2015-08-26 | Gilead Calistoga Llc | NEW QUINOXALINE INHIBITORS OF THE PI3K PATH |
| GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
| JO3210B1 (ar) | 2011-10-28 | 2018-03-08 | Merck Sharp & Dohme | مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة |
| GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| PT2771342T (pt) | 2011-10-28 | 2016-08-17 | Novartis Ag | Derivados de purina e o seu uso no tratamento de doença |
| GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
| US9221804B2 (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
| WO2015144808A1 (en) | 2014-03-26 | 2015-10-01 | Astex Therapeutics Ltd | Combinations of an fgfr inhibitor and an igf1r inhibitor |
| JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
| AU2015238301B2 (en) | 2014-03-26 | 2020-06-25 | Astex Therapeutics Ltd | Combinations |
| JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
-
2011
- 2011-10-28 GB GBGB1118675.6A patent/GB201118675D0/en not_active Ceased
-
2012
- 2012-10-26 RU RU2014121496A patent/RU2629194C2/ru active
- 2012-10-26 SI SI201231612T patent/SI2776436T1/sl unknown
- 2012-10-26 CN CN201280065193.8A patent/CN104011052B/zh active Active
- 2012-10-26 IN IN987MUN2014 patent/IN2014MN00987A/en unknown
- 2012-10-26 ES ES12795836T patent/ES2731216T3/es active Active
- 2012-10-26 BR BR112014010179-5A patent/BR112014010179B1/pt active IP Right Grant
- 2012-10-26 AU AU2012328167A patent/AU2012328167B9/en active Active
- 2012-10-26 DK DK12795836.1T patent/DK2776436T3/da active
- 2012-10-26 KR KR1020147010847A patent/KR102027602B1/ko active Active
- 2012-10-26 LT LTEP12795836.1T patent/LT2776436T/lt unknown
- 2012-10-26 WO PCT/GB2012/052669 patent/WO2013061077A1/en active Application Filing
- 2012-10-26 CA CA2853367A patent/CA2853367C/en active Active
- 2012-10-26 US US14/354,793 patent/US9309241B2/en active Active
- 2012-10-26 EP EP12795836.1A patent/EP2776436B1/en active Active
- 2012-10-26 HU HUE12795836 patent/HUE044576T2/hu unknown
- 2012-10-26 JP JP2014537727A patent/JP6022588B2/ja active Active
- 2012-10-26 HR HRP20190994 patent/HRP20190994T1/hr unknown
- 2012-10-26 MX MX2014004859A patent/MX349004B/es active IP Right Grant
-
2015
- 2015-09-16 US US14/855,986 patent/US9527844B2/en active Active
-
2016
- 2016-10-31 US US15/339,148 patent/US9757364B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN00987A (OSRAM) | ||
| IN2014MN00948A (OSRAM) | ||
| IN2014MN00986A (OSRAM) | ||
| IN2014MN02049A (OSRAM) | ||
| IN2014MN00988A (OSRAM) | ||
| IN2014MN02069A (OSRAM) | ||
| IN2012MN02591A (OSRAM) | ||
| PH12015500274B1 (en) | Alkylpyrimidine derivatives for the treatment of viral infections and further diseases | |
| PH12016501139A1 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| IL236221A (en) | History of theophyridone and pharmacological preparations containing them for the treatment of diseases | |
| TN2015000278A1 (en) | Autotaxin inhibitors | |
| PT2925757T (pt) | Compostos e composições para o tratamento de doenças parasitárias | |
| PH12015500713B1 (en) | Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases | |
| IL231926A (en) | Factors that induce apoptosis for the treatment of cancer and autoimmune and autoimmune diseases and their pharmaceutical compositions | |
| MX349224B (es) | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa. | |
| EP2709632A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF SKIN DISEASES | |
| IN2014DN03010A (OSRAM) | ||
| HUP1100290A2 (en) | Combination compositions for the treatment of proliferative diseases | |
| AU2011900519A0 (en) | Drug compositions for the treatment of insomnia | |
| TN2013000202A1 (en) | Spiro-oxindole mdm2 antagonists | |
| HUP1100245A2 (en) | Pharmaceutical composition for the treatment of wounds |